Trial Profile
Phase I Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2021
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned End Date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.